Compare Panacea Biotech with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUN PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUN PHARMA PANACEA BIOTECH/
SUN PHARMA
 
P/E (TTM) x 11.7 26.9 43.4% View Chart
P/BV x 2.8 2.3 120.8% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PANACEA BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
SUN PHARMA
Mar-19
PANACEA BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs364679 53.6%   
Low Rs129375 34.4%   
Sales per share (Unadj.) Rs96.8121.1 79.9%  
Earnings per share (Unadj.) Rs-12.413.4 -92.8%  
Cash flow per share (Unadj.) Rs-2.920.7 -13.8%  
Dividends per share (Unadj.) Rs02.75 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs50.4172.6 29.2%  
Shares outstanding (eoy) m61.252,399.26 2.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.54.4 58.5%   
Avg P/E ratio x-19.939.4 -50.4%  
P/CF ratio (eoy) x-86.425.5 -339.2%  
Price / Book Value ratio x4.93.1 160.2%  
Dividend payout %020.6 0.0%   
Avg Mkt Cap Rs m15,1011,264,650 1.2%   
No. of employees `0002.517.5 14.1%   
Total wages/salary Rs m1,51659,671 2.5%   
Avg. sales/employee Rs Th2,401.916,608.1 14.5%   
Avg. wages/employee Rs Th614.23,409.6 18.0%   
Avg. net profit/employee Rs Th-307.91,833.8 -16.8%   
INCOME DATA
Net Sales Rs m5,928290,659 2.0%  
Other income Rs m8210,255 0.8%   
Total revenues Rs m6,010300,914 2.0%   
Gross profit Rs m84563,076 1.3%  
Depreciation Rs m58517,533 3.3%   
Interest Rs m1,0065,553 18.1%   
Profit before tax Rs m-66450,246 -1.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m996,009 1.6%   
Profit after tax Rs m-76032,093 -2.4%  
Gross profit margin %14.321.7 65.7%  
Effective tax rate %-14.912.0 -124.3%   
Net profit margin %-12.811.0 -116.1%  
BALANCE SHEET DATA
Current assets Rs m5,603310,692 1.8%   
Current liabilities Rs m6,910173,396 4.0%   
Net working cap to sales %-22.047.2 -46.7%  
Current ratio x0.81.8 45.3%  
Inventory Days Days20699 207.8%  
Debtors Days Days84112 75.1%  
Net fixed assets Rs m9,941232,477 4.3%   
Share capital Rs m612,399 2.6%   
"Free" reserves Rs m3,026411,691 0.7%   
Net worth Rs m3,087414,091 0.7%   
Long term debt Rs m5,70715,226 37.5%   
Total assets Rs m16,076646,938 2.5%  
Interest coverage x0.310.0 3.4%   
Debt to equity ratio x1.80 5,028.1%  
Sales to assets ratio x0.40.4 82.1%   
Return on assets %1.55.8 26.3%  
Return on equity %-24.67.8 -317.7%  
Return on capital %3.910.2 38.5%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60066,025 2.4%   
Fx outflow Rs m1,13138,610 2.9%   
Net fx Rs m46927,415 1.7%   
CASH FLOW
From Operations Rs m1,18021,965 5.4%  
From Investments Rs m553-6,813 -8.1%  
From Financial Activity Rs m-1,644-27,305 6.0%  
Net Cashflow Rs m90-8,442 -1.1%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.1 11.7%  
FIIs % 1.3 23.0 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 8.3 284.3%  
Shareholders   10,259 133,026 7.7%  
Pledged promoter(s) holding % 35.1 0.5 6,617.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ASTRAZENECA PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Oct 16, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - SANOFI INDIA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS